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nemia in Chronic Heart Failure
hould We Treat It and How?*
ichel Komajda, MD, FESC
aris, France
n recent years, the occurrence of anemia in patients with
hronic heart failure (CHF) has received increasing atten-
ion. The prevalence of anemia reported in cohorts of
atients or controlled randomized trials varies considerably
1,2). This variation is due not only to different recruitment
rofiles but also to the fact that there is no consensus on the
efinition of anemia in cardiology and, consequently, that
ifferent threshold hemoglobin or hematocrit levels have
een used. However, general agreement exists that anemia is
frequent comorbidity and that it is associated with
ncreased mortality or rates of hospital admissions and
ecreased quality of life or exercise tolerance, particularly
hen severe (3,4). There is also evidence suggesting that
See page 753
nemia is an evolving process and that new-onset anemia is
ommon in CHF (5,6). The mechanism of anemia in CHF is
matter of debate and appears multifactorial. Impaired eryth-
opoietin (EPO) production or resistance, iron and other
ematinic deficiencies, inflammation through cytokine activa-
ion, and hemodilution can play a role in the development of
nemia in patients with CHF (7). Interestingly, some CHF
edications, namely angiotensin-converting enzyme inhibitors
r some beta-blockers, also may be associated with the occur-
ence of anemia (5,8). In this context, different medical
nterventions have been proposed to correct anemia. Two
istinct strategies can be discussed: iron supplementation
nd/or subcutaneous EPO administration. The article by
onikowski et al. (9) in this issue of the Journal is an elegant
andomized, double-blind, and placebo-controlled study using
arbepoietin alpha, a long-acting erythropoiesis-stimulating
rotein or placebo in patients with symptomatic CHF, low
jection fraction, and anemia defined by a hemoglobin con-
entration from 9 to 12 g/dl. The primary end point was the
hange from baseline in exercise tolerance measured by peak
xygen consumption (VO2) adjusted for body weight. Other
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.hFrom the Department of Cardiology, University Pierre Marie Curie, Paris and Pitie
alpetriere Hospital, Paris, France.nd points included exercise duration, hemoglobin, New York
eart Association (NYHA) functional classification, quality of
ife, brain natriuretic peptide, and hospitalizations. After 26
eeks of observation, a significant increase in hemoglobin
oncentration was observed in patients receiving darbepoietin
lpha compared with those receiving placebo. The mean
hange between the 2 groups was 1.5 g/dl. However, there was
o difference in peak VO2, absolute peak VO2, and exercise
uration, although the observed changes went into the right
irection. The only favorable difference observed with darbe-
oietin alpha was an improvement in self-reported patient
lobal assessment, whereas no difference was observed when
sing 2 other disease-specific instruments, the Kansas City
ardiomyopathy questionnaire and theMinnesota Living with
eart Failure Questionnaire, or in NYHA functional class.
inally, there was no significant difference in the change in
lasma brain natriuretic peptide or hospitalization rate. No
ajor safety issue was reported by the investigators.
These results are in contradiction with previous small
tudies suggesting that EPO improves functional capacity,
uality of life, and exercise tolerance (10,11). However,
ost of the preliminary reports had limitations, including
ack of double-blind or placebo-controlled design, whereas
he article by Ponikowski et al. (9) used a rigorous double-
lind, placebo-controlled design. One potential explanation
or the lack of impact of the observed increase in hemoglo-
in concentration on most of the efficacy end points is the
elatively small sample size, and, indeed, there was a trend
oward an improvement of all the efficacy parameters.
Another potential factor is the inclusion of mildly symp-
omatic heart failure patients, as more than 50% of those
eceiving darbepoietin alpha were in NYHA functional class
I. We do not know at present whether only severely
ymptomatic patients or patients with severe anemia might
enefit of EPO or whether a broader spectrum of patients
ould improve under this therapy.
As they stand, however, the results of this study suggest that
orrection of low hemoglobin levels in patients with CHF is
afe and improves their quality of life. They support the idea of
onducting larger placebo-controlled randomized trials with
PO in anemic patients with CHF to assess the safety and the
otential benefit of this intervention on hospitalizations, func-
ional capacity, quality of life, and exercise tolerance. We need
o learn more on EPO dose regimens; definition of patients
ikely to benefit from EPO, including functional severity,
emoglobin threshold for intervention, and target values; and
n the long-term safety. Until this information is available, we
annot make any recommendation on the potential benefit of
PO in the management of CHF.
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